

Supplementary

- 8 Bendon CL, Furniss D, Giele HP. Comparison of outcomes of peripheral nerve schwannoma excision in neurofibromatosis type 2 patients and non-neurofibromatosis type 2 patients: a case control study. *J Plast Reconstr Aesthet Surg* 2015;68(9):1199–1203
- 9 Taylor LA, Lewis VL Jr. Neurofibromatosis type 1: review of cutaneous and subcutaneous tumor treatment on quality of life. *Plast Reconstr Surg Glob Open* 2019;7(1):e1982
- 10 Wishart JH. Case of tumours in the skull, dura mater, and brain. *Edinb Med Surg J* 1822;18(72):393–397
- 11 Feiling A, Ward E. A familial form of acoustic tumour. *BMJ* 1920;1(3093):496–497
- 12 Gardner WJ, Frazier CH. Bilateral acoustic neurofibromas: a clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members. *Arch Neurol Psych* 1930;23(2):266–302
- 13 Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management. *Handb Clin Neurol* 2013;115:957–967
- 14 Hulsebos TJM, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. *Am J Hum Genet* 2007;80(4):805–810
- 15 Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. *Lancet* 2009;373(9679):1974–1986
- 16 Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. *Q J Med* 1992;84(304):603–618
- 17 Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. *Am J Med Genet* 1994;52(4):450–461
- 18 Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. *Neurosurgery* 1996;38(5):880–885, discussion 885–886
- 19 Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. *Arch Dis Child* 1999;81(6):496–499
- 20 Nunes F, MacCollin M. Neurofibromatosis 2 in the pediatric population. *J Child Neurol* 2003;18(10):718–724
- 21 Ruggieri M, Iannetti P, Polizzi A, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. *Neuropediatrics* 2005;36(1):21–34
- 22 Sperfeld AD, Hein C, Schröder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. *Brain* 2002;125(Pt 5):996–1004
- 23 Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. *Acta Neuropathol* 2012;123(3):295–319
- 24 Ferner RE, O'Doherty MJ. Neurofibroma and schwannoma. *Curr Opin Neurol* 2002;15(6):679–684
- 25 Tsai WC, Chiou HJ, Chou YH, Wang HK, Chiou SY, Chang CY. Differentiation between schwannomas and neurofibromas in the extremities and superficial body: the role of high-resolution and color Doppler ultrasonography. *J Ultrasound Med* 2008;27(2):161–166, quiz 168–169
- 26 Belakhova SM, Rodriguez FJ. Diagnostic pathology of tumors of peripheral nerve. *Neurosurgery* 2021;88(3):443–456
- 27 Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. *Pediatrics* 2009;123(1):124–133
- 28 Mautner VF, Friedrich RE, von Deimling A, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma. *Neuroradiology* 2003;45(9):618–625
- 29 Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W III, Plotkin SR. Health-related quality of life of individuals with neurofibromatosis type 2: results from the NF2 Natural History study. *Otol Neurotol* 2016;37(5):574–579
- 30 Merker VL, Bredella MA, Cai W, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. *Am J Med Genet A* 2014;164A(6):1431–1437
- 31 Cosetti MK, Golfinos JG, Roland JT Jr. Quality of life (QoL) assessment in patients with neurofibromatosis type 2 (NF2) Otolaryngol Head Neck Surg 2015;153(4):599–605
- 32 Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. *Cancer* 1986;57(10):2006–2021
- 33 Salar M, Kaye MB. Multiple schwannomas of the median nerve: a case report and review of the literature. *J Orthop Case Rep* 2020;10(6):60–63
- 34 Guha D, Davidson B, Nadi M, et al. Management of peripheral nerve sheath tumors: 17 years of experience at Toronto Western Hospital. *J Neurosurg* 2018;128(4):1226–1234
- 35 Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. *J Neurosurg* 2005;102(2):246–255
- 36 Levi AD, Ross AL, Cuartas E, Qadir R, Temple HT. The surgical management of symptomatic peripheral nerve sheath tumors. *Neurosurgery* 2010;66(4):833–840
- 37 Mizushima H. Neurological deficits before and after surgical resection of schwannomas in the upper extremities. *J Reconstr Microsurg* 2016;32(5):371–377
- 38 Ujigo S, Shimose S, Kubo T, Fujimori J, Ochi M. Therapeutic effect and risk factors for complications of excision in 76 patients with schwannoma. *J Orthop Sci* 2014;19(1):150–155
- 39 Artico M, Cervoni L, Wierzbicki V, D'Andrea V, Nucci F. Benign neural sheath tumours of major nerves: characteristics in 119 surgical cases. *Acta Neurochir (Wien)* 1997;139(12):1108–1116
- 40 Dozois EJ, Wall JCH, Spinner RJ, et al. Neurogenic tumors of the pelvis: clinicopathologic features and surgical outcomes using a multidisciplinary team. *Ann Surg Oncol* 2009;16(4):1010–1016
- 41 Kim SM, Seo SW, Lee JY, Sung KS. Surgical outcome of schwannomas arising from major peripheral nerves in the lower limb. *Int Orthop* 2012;36(8):1721–1725
- 42 Zhai H, Lv Y, Kong X, Liu X, Liu D. Magnetic resonance neurography appearance and diagnostic evaluation of peripheral nerve sheath tumors. *Sci Rep* 2019;9(1):6939